A drug with a new mechanism of action is always a welcome addition in the fight against HIV. Maraviroc was recently approved by the FDA and is the first of the chemokine receptor 5 antagonists to enter the market.
Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.